August 13th
2008
1:59 PM
I am still experiencing hot flushes even though I am post menopausal. I reckon it could be down to the Lisinopril pills. My dose has been doubled to 20mg from 10mg. Could this be the case? Has anyone else had these symptoms?
-- By sylviahough | Reply | (5) replies | Private Message me
October 19th
2008
10:40 PM
A series of articles published by the Boston Globe in 2001 revealed
that the number of children enrolled in clinical trials in 1997 was
16,000: by 2001, the number reached 45,000. The Globe found that children
enrolled in clinical trials had suffered and died, and that ethical
standards had been violated.
Financial incentives for parents, physicians, and researchers had undermined
children's welfare. Children are currently being recruited with Toys
'R Us gift certificates. Parents in need of money are offered as much
as $1,000 to "volunteer" their children for drug experiments that involve
risks of harm. The physicians
who are engaged in such coercion receive as much as $5,000 in kickbacks
(euphemistically called, "referral fees") for the recruitment of children.
None of these disturbing facts were brought to the attention of the
U.S. Congress when it passed the Best Pharmaceuticals for Children Act
in 2002. The evidence, however, shows that children are being deprived
of existing, more protective federal regulations under 45 CFR 46, Subpart
D, and are being subjected to foreseeable risks of harm and discomfort,
often on the basis of a presumed potential risk for which there is no
empirical evidence. The FDA
acknowledged that before FDAMA the use of children as subjects in phase
I safety drug studies "had been primarily limited to life threatening
diseases and children who had the disease" in question.
The policy prior to FDAMA protected children from harmful experiments
in accord with the 1983 federal regulations (45 CFR 46.404-409). Following
passage of FDAMA, however, federal policy broadened the criteria for
inclusion of children in research generally and for participation of
children entered in high-risk experiments. In 1999 the FDA acknowledged
that the post-FDAMA policy change "led to an increasing number of proposals
for studies of safety and pharmacokinetics, including those in children
who do not have the condition for which the drug is intended."[64
-- By flindy | Reply | Private Message me